375P Stereotactic radiotherapy (SRT) in combination with aumolertinib to treat intracranial oligometastatic non-small cell lung cancer (NSCLC): A phase II, prospective study

The noval third-generation EGFR-TKI aumolertinib have better initial therapeutic efficacy for intracranial lesions than first-generation TKI. Moreover, Stereotactic radiotherapy (SRT) is highly effective and less toxic for a limited number of intracranial metastases. Research suggested that existing lesions progression were likely to occur before new distant metastasis, so more effective local treatment including SRT after first-line TKIs progression may bring benefits. We aim to investigate the activity and safety of daily aumolertinib followed by SRT in patients with intracranial oligometastatic NSCLC.